Skip to main content
. 2014 Jan 22;2014:342986. doi: 10.1155/2014/342986

Figure 3.

Figure 3

Overall survival curves in the imatinib plus BSC group (solid line) and the BSC alone group (dotted line). Median overall survival times were 22 months and 4 months, respectively. The hazard ratio for imatinib plus BSC was 0.332 (P = 0.058, log-rank test). BSC, best supportive care.